Document Detail


Advances in pemphigus therapy.
MedLine Citation:
PMID:  18506357     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The pemphigus variants represent a group of potentially life-threatening autoimmune mucocutaneous blistering diseases. Though systemic corticosteroids have dramatically reduced the rate of disease mortality, current therapeutic options are limited by their toxicity profiles. Advancements in our understanding of the molecular mechanisms involved in the pathogenesis of pemphigus have translated into the development of novel therapies. However, few treatments have been subject to randomized controlled trials to firmly establish therapeutic efficacy. Herein, we focus on the new and emerging therapies in the management of pemphigus.
Authors:
V Prajapati; P R Mydlarski
Related Documents :
18567837 - Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-ol...
10426357 - Monitoring relapsing remitting ms patients.
18348877 - The use of hyperbaric oxygen therapy in ophthalmology.
23244617 - The thioredoxin system as a therapeutic target in human health and disease.
19623287 - Mastocytosis: a disease of the hematopoietic stem cell.
18560237 - Late-onset autoimmunity: the paradigm of primary biliary cirrhosis--a mini-review.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Skin therapy letter     Volume:  13     ISSN:  1201-5989     ISO Abbreviation:  Skin Therapy Lett.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-05-28     Completed Date:  2008-07-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9891441     Medline TA:  Skin Therapy Lett     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  4-7     Citation Subset:  IM    
Affiliation:
Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Inflammatory Agents / therapeutic use
Glucocorticoids / therapeutic use*
Humans
Immunoglobulins, Intravenous / therapeutic use
Immunologic Factors / therapeutic use
Immunosorbents / therapeutic use
Immunosuppressive Agents / therapeutic use
Pemphigus / therapy*
Photopheresis
Plasmapheresis
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Glucocorticoids; 0/Immunoglobulins, Intravenous; 0/Immunologic Factors; 0/Immunosorbents; 0/Immunosuppressive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Topical therapy for the management of childhood psoriasis: part I.
Next Document:  Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal ox...